Compare · EW vs NAOV
EW vs NAOV
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and NanoVibronix Inc. (NAOV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and NAOV operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW carries a market cap of $60.62B.
- EW has hit the wire 12 times in the past 4 weeks while NAOV has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for NAOV).
- Company
- Edwards Lifesciences Corporation
- NanoVibronix Inc.
- Price
- -
- -
- Market cap
- $60.62B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
NanoVibronix Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 101 shares, decreasing direct ownership by 0.69% to 14,606 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $64,531 worth of shares (619 units at $104.25) as part of a pre-agreed trading plan (SEC Form 4)
- CEO Zovighian Bernard J exercised 23,100 shares at a strike of $72.68 and sold $2,379,779 worth of shares (23,100 units at $103.02) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr exercised 48,900 shares at a strike of $72.68 and sold $5,039,311 worth of shares (48,900 units at $103.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 22,798 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
Latest NAOV
- ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
- ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line
- ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
- ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription
- ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
- ENvue Medical to Ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026
- SEC Form 3 filed by new insider Pionati Pellegrino
- SEC Form 3 filed by new insider Johnson David Ian
- SEC Form 424B3 filed by NanoVibronix Inc.
- ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK